PODD - Earnings call transcript Q2 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Second Quarter of 2018 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will be given at that time.

As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Deborah Gordon, Vice President, Investor Relations and Corporate Communications.

Deborah R. Gordon

Nicole. you, Thank thank XXXX and joining our for Good call. you quarter earnings second afternoon, for

Joining Patrick and our on in full-year discussing guidance also Officer; today Officer. Petrovic, Senior press available our me are President website. The President third Officer; second Chief Vice will be call our and Shacey and replay Executive of Chief Chief Operating and and and archived this quarter Levitz, Sullivan, Michael IR quarter of Financial Chairman section the our website release XXXX results and is

we our inform Such during those all statements basis. percentage materially different quarter in Before be year-over-year actual begin, release With and referenced include call involve that statements. to our Also, I on future of call and Pat. any turn course from unknown changes in that, otherwise over factors to would may filings SEC. Insulet cause implied second you uncertainties in by and to dollar the Harbor a forward-looking and by may such and like earnings commentary the known results regarding unless made be this results be certain the company's Safe risks the will statement I'll with financial stated, that

Patrick J. Sullivan

good the to of gross our greater expand increase on markets, annual operations excess the be market, on delivered to value the revenue We full growth directly achieved another basis margin the in will lots to with representing quarter XX%, growth European for U.S. track year-over-year we QX the interact year million Omnipod XX% of on and progress XXXX business Drug Shacey gross positive achieve quarter's in are accelerate a then operations and significant We year, direct significant will international guidance. a and average basis. with XXX When the milestones, opening of questions. remarks, this operating a to run in return many specifically income for market, our and joined tailor and confined positive exceeding results with of operating achieved with Mike income normal from $X.X to our Europe After Insulet's four inflection X. Exiting this is benefits, installed of of Deb, basis revenue of pricing anticipated will opportunity I $XXX inventory of to European transition QX this Insulet an afternoon, Thanks, on improvement. my margin operations our room was inventory on point Europe QX. identified then everyone. of rate. distributor an we'll open expectations. million of for by quarter than with million, control the transitioned $XXX.X ability July in will for to due Delivery provide Omnipod nearly second to realized years other detail revenue The meet key history. up ago, in time when I a than first follow in in excess second revenue and XXX quarter to the we needs direct international call lots innovation direct pipeline base, company XX%, the our International impact a our revenue points to grow. was improve We expansion less and

objective. two July this direct very X, planning of after Going we and years big year was our building work met in very lot deal. a Europe, in of and On one important Europe of presence a successfully

for which logistics We the and July people and product all have maintained on on Omnipod care, in through milestones X, number operational course XX/X been leading distribution of Europe our across our our continent. and Since of staffed customer over we've We with midnight shipping orders met priority. teams across transition. and of up one care to of stroke XXX are users the the fully supporting the was customers, ground XXX% taking Europe, all continuity

Our commercial a calling and positive patients onboarding been teams impact. have are and efforts already on these new having customers very

the of international July, For starts strong. and were month new shipments patient

end-user notably our direct Omnipod a business. within in markets patient placed new of fact, reflecting our demand all run In the than starts rate. vibrant orders, higher in markets Intermediaries were strong have historical for

the We Diabetes our I'd was an American with announced innovation company at a of the update in hit as of month. June business key limited strategic foundation interactions gaining quarter. our System. a now big achieved DASH European for in On roadmap, of June are on last and this market through entered initiatives. X, milestone innovation European upon we are FDA Omnipod the the of including Association pipeline, our extremely our we release strength On to insulins concentrated the customers. just our we we some like serves in DASH second our HORIZON. clearance DASH major meeting insights direct confident based the exciting market you all valuable provide other

Omnipod Sponsors: a added of we the wins quarter. the at Turning to XXXX. market two a Express with early early in whom second coverage broad benefit Scripts will have great are Medicare access, both Part access that and as Plan These of covered secured start indicator D Magellan, we

our manufacturing new we're second facility to manufacturing, to assembly making rapid securing state support highest we're Part margin expect to state-of-the-art to redundancy new our sponsors headquarters in target contribute the in for Medicare plans. Medicare company's our as In early install in to our win of the are as Based were with in overseas, reimbursement making building starts progress our the additional existing facility Manufacturing great facility achieving strides D with and This gross XX% track begin great company growth. later this the early will on quarter XXXX. We're Massachusetts. We on year in this history. and progress making production the equipment with U.S. automated XXXX. well also patient operations capacity in and our provide UnitedHealthcare, will

to Before the to speed call despite direct is I over a last Shacey, the reiterate Mike month Europe business to that and in operations bump was transition single tremendous the I'd hand throughout like strong. and Europe, success

XX% with XXXX it We are are and that, in way we to margin over $X the profitability. Michael? With Omnipod on gross billion goals I'll pleased achieve growth business our and our turn of revenue, Mike. above-market our to well of

Michael L. Levitz

Thank you, Pat.

channel unfavorable second in revenue our double-digit the as demonstrated in even higher impact after transitioned from distributor inventory we performance of financial growth the Europe. former quarter than Our expected

Our moved reaching EBIT this to margins quarter. XX% significantly, gross rose and we positive

to on we are are operating As a a significant throughout very of am pleased result, full-year positive XXXX. and and confirm in well fundamentals growth achieve in growth that year of of top target for setting strong our our The to bottom-line I great history. the first will profit business for we track Insulet's XXXX, up time deliver us

end growth profitability. We million confident Total are of In grew access quarter highly revenue early we which for was the upper into high momentum base long-term offset by and another above due led expected our projections States, company the recent XX%, in both the revenue. international guidance market had our wins. United in by and high Diving achieving results. revenue the customer our growth Omnipod range, to than from with reaching up U.S., lower fast-growing $XX.X XX%, growth

from the inventory X%, channel of grew And is approximately healthy revenue Europe, our Apart from in underlying Omnipod our Drug was our to great former reduction momentum. revenue for million. results year. quarter $XX of roughly International near-term line European a The than the Our channel impact repurchase our million. with of guidance Delivery product totaling distributor. of inventory, in in business inventory due million midpoint the $XX.X in $XX.X with That's the last were million $X.X Europe in lower including very this line

gross to margin. Turning

favorable This the continued in XXX drive lower significant in manufacturing points. quarter, sales. margin due distributor on expansion as to well as This basis chain was mix gross tremendous we supply continued XX%, quarter reaching and improvements operations, our to international up

direct gross As historic a points XX% adds to we view base. now basis operational and operations transition Europe, of rate, the new our to successful run our our in XXX margin as result which improvements

therefore, expectations in a are, XXXX that XX%, to pleased track also are year-over-year I'm raising points. margin basis our XX% to gross to full say longer on year objective XXX term increase We XXXX. of our of we over achieve expansion

from totaled Moving our in P&L, $XX million, our operating included our run down with line million up to with line in $XX expectation. spending $XX rate of million. in expected million, Europe $XX.X annual This to expenses

ended We cash invest the That's million manufacturing U.S. positive $X.X year growth chain the now plan. end to due a and million in As $XXX and $XXX our last operating delivered our profit with from of will quarter, we and gross we in primarily of on million. result XXXX revenue expansion line supply update quarter investments. down at outlook. I our operations with the in margin of you in expenditures capital as

due to year, we lowering Delivery raising revenue to our for XX%. product of and is $XXX we expectations company both and $XXX our million. we International XX% million. That's expectation guidance product impact Omnipod U.S. our our growth ranges total revenue For $XXX inventory channel to to representing the the our the compared of of range in expect the full short-term Drug This level, million line million $XXX midpoint of are in to Omnipod for revenue previous On of are line Europe.

growth commercial to given the XX%. our range Omnipod, customer strong representing reflects we of expect market momentum wins of access recent confidence $XXX to U.S. a high XX% now base, This of overall. growth and $XXX For million, increase million in our

we we decline our our to $XX $XXX growth XX%, million, of of to from our X% Delivery, That from to $XX Drug reflects transition-related XX%. million XX% guidance our historic part of distributor our to by to And pricing expectations direct, of previous channel in for inventory. revising of For International to million. mid-year we the representing are former distributor million million and Europe, represents expectation from uplift Omnipod, million. XX% $XXX range $XXX raising inventory a growth XXXX estimate that down are to offset are This approximately now repurchase our in an $XXX range

of $XX Omnipod $XXX.X representing growth XX% of $XX.X That's includes X% and of XX%; Delivery third to XX%. XX%, growth million Omnipod million. International million, For to expect $XX $XX to This company to million million, $XX U.S. XX% to Drug representing $XX.X million $XXX.X of growth quarter, million million, of XX% X%. representing the of of to to to down revenue we total

of impact International are the Europe. will a Omnipod model encourage the you we and You channel usual closer range in is range than midpoint inventory we the due providing to wider notice near-term of to the for bit to

Finally, we're of XXXX track excited year full to to deliver this In be another on reaffirming year margin for XXXX we our high the low-single-digit are of percentage in expectation year Insulet. and summary, operating profitability execution successful operating and growth range. is

drive for the to expansion top as strong significant gross year. continue growth and income We as margin operating line positive well

continue just getting now started. to areas We XXXX confident and all also over and exceptional are execution call We business revenue of I our reaching will our the deliver are margin highly targets. Shacey. turn truly to about in really

Shacey Petrovic

our our Thanks achieve execute, progress and on continues Mike. strategic business, to imperatives. key make significant our Across team great milestones

meet revenue did not our QX international results expectations. Our

off is However, short-term. have customer effectively expectations. am it for confident we a have I identified the Mike, impact of start that source, like and solved and brief overview will our base I the with Pat

we a growth. expect XX% range customer XX% to base now of U.S. For Omnipod,

our this expect is our some progress Despite short-term strong. be inventory impact, and we've XX% XX% international range. we Shortly, expected the share For I'll of European great our learnings the and since key reaffirming underlying of business customer to midpoint at are made growth to base, incredibly transition.

to would remarks. discussed upon his in expand Pat First, what like I

became contain While we that was inventory negotiations buy European from us impact. how inaccurate in intermediaries, ascertain to inventory the the order effort was we was and contract disclosed reduce made financial our with much at inventory it and distributor understated. in there evident the in channel the in excess as every its former the previous confusion to Also, our to We advanced to distributor former decided reporting field. excess during and our June, distributor market inventory in transition, our the back

the market desire prime for commercial for into European better reason in visibility all was Our assuming operations a Europe.

business to the fundamental better about the the of And into in our into and markets are there further and incredibly business Europe closer that excited penetration existing confirmed opportunity team's across have to We customers our grow other grow to to more serve our European we tremendous that of Early view execution now the transition. market much our business, this own much markets. strength and further we European our effectively. indications place for the have global is are team running expand

this We educating for days clinicians, have and fully business training that XX is in commercial team just short staffed our market and patients. payors had insights, negotiating over with period gathering

We in languages. support five are XX/X clinician product providing support and

shipped International have with serve, including with and regulatory improved for bodies. market diabetes Europe. the we our established and and recently of intermediary We EU partnership patients are Federation strong advocacy And markets. every to our distributors, support across care our our direct to every with we contracted leaders relationships We've to we key opinion across Diabetes thousands announced

markets, hundreds passion Care experience direct a execution have the our expertise teams. Customer contagious I of no kick continue I by onboarded Lisbon patients be already and to Our our team talented during in I all energy sales be we the tremendous of drive our impressed and great of and had to value. pleasure to our as our new place with European team. right and in team London official long-term of and well office our The deep clinical team the in testament doubt were excitement have as to Insulet across the field has off. European

as forward infrastructure our We year trajectory you progresses. our drive sharing have growth I And success. and significant built to a the with powerful support to accomplishments look to

our smaller represent international if be how operations just well of didn't remiss our business, Canadian to results our area executing and grow team a percentage of mention our is business. would commercial although I Additionally, strong I deliver this

have We province are selected the very preferred of as the Columbia. pump British been diabetes to insulin with in for pleased individuals

reimbursement the criteria eligibility for a restriction The eliminated individual Now, coverage below the XX for extended therapy years as who meets receive of lifetime province and benefit Omnipod. age an will also or pump patients.

look ready story success differentiated have another technology. to and acceptance This and are yet that the of We patients supports of that and global these for change. waiting this serving adoption benefits Omnipod forward been many the our is

States, in United we our headway. on access Moving market to efforts, to the continue make terrific

for Omnipod recent our these our Scripts current the trajectory. mentioned, covered important and Express and by strengthened Pat wins As UnitedHealthcare, They growth and Magellan future outlook long-term have also users represent plans. wins

positive into and we coverage the went X, effect momentum realizing this on impact already UnitedHealthcare are accelerate April We from XXXX. to expect the that into

We with Sponsors have and are their and million for that on be call strengthened QX also by for working XXXX will And benefits Omnipod, to X.X coverage position closely insight Plan our the so Omnipod our Medicaid we formulary Medicare this on we Part bringing D further lives. Medicare included lives will covered quarter, XX adding about approximately coverage past our greater Medicaid million covered total timing.

expect we here, headway into access and great grow year made we've this XXXX. Medicaid throughout continue to While to

thrilled where are for was booth, in overwhelmingly providers Omnipod had a with DASH individuals feedback DASH have great and and a ADA June. and We hands-on big experience well efforts, unveiling DASH our a received to were the innovation healthcare received was At from we positive. apps at our Moving to mobile hit. had VIEW clearance Omnipod our DISPLAY very on FDA

Customer to CGM for on by their caregivers to view of enthusiastic, the and iPhone. app was allows for users the of Bluetooth Omnipod their enabled response loved such have new a data the while ability their reminder, DISPLAY user an smartphones, their to particularly DASH's as the communication, remotely a features allows VIEW integrated As data the see data app on incredibly view ones. Dexcom

ADA to including date presentations, in at use we our nine with U-XXX, Austria, and largest had addition, and Germany Omnipod System with Lilly clinical data. Control data Glucose our Omnipod Omnipod Automated presence In Horizon

our the highlighted Omnipod overall For data excellence. by ADA row, second for year a in its was Horizon

development third study, free-living make in on about to continue olds IDE two- conditions. performance We lot in and system to clinical six-year are of progress our half second development the learning the in a Horizon

a great pre-pivotal wrap market into have into IDE. We now we will or the We DASH. up entered and into head Last release study system first highlighting DASH system. either the we of expect its Customers receiving and a round ease unparalleled are for intuitive this final our will interface limited performance of on September the feedback and the use. touch screen users in month, are new of on the of

capturing move opportunity to this over burden the We the next technology into for and to our platform, in better we is through and transition have D experience our business. coverage patient turnaround, international will few a not operations newly usage us scale the DASH. faster European to DASH and model. meaningful short and this a designed opportunities Market quarters just Launching significantly DASH successful for for today market of well for our responding an the Payors and In through PDM for business in an this will Access pharmacy in documentation with just of the unique we customer more also pharmacy By with pharmacy. cost the full A and we to full to access channel. for market both people a release improve new market Omnipod quarter largely channel percentage very economics convenience. remarkable to through increase e-prescription pharmacy pay-as-you-go are weeks, our for the summary, Part our early team to PDM expect establish focusing from reduces access goes is adoption the are just steam to are have and release, on a business of potential XXXX. this moved limited but of no-cost access exciting And enable patients removing barriers channel. two the technology. for a reduced provides with secured in Thanks upfront Omnipod during ahead expanded proceeding and and more positioned well pleased potential DASH is and clinics it CMS's benefit work designation,

access and tremendous creation. the to let's to in continue our pipeline make value questions. open ability market efforts. long-term that, We for operator, With and achieve innovation great progress advancing growth confidence call have I Insulet's

Operator

you. Thank

line Morgan first Our of from David question Lewis of Stanley. the

Your line is open. now

David Ryan Lewis

my Guys, afternoon. blow business. to I'm the going questions on Good here ex-U.S. two

happened ex-U.S. description Shacey, what's I of So, think your

but I think think, people sense to a clear, of. I better it's pretty get want

can can what Mike inventory is burden as the size confidence the fourth you burden, you can state well ex-U.S. I on get you this by As back And of that or quick the quarter? through follow-up had a and your there get

Shacey Petrovic

Yeah. Sure. Okay.

that seven weeks approximately channel, of is five are estimate over four eight weeks we to two and So there QX. about to in to approximately three QX. spread in QX QX the inventory in weeks and which That's

we And impact also an so, about in expect in million and $XX was that QX. QX an impact $XX million

those In those we terms are in numbers, confident very are of how we numbers. confident in

think why a took into I last the we insight exactly the getting over. business seeing just this XX market. level of different we're We're over days

all have utilization of validate intermediaries, with information, able customer clinicians of to We our been just this interacted insight. patients and rates now all all have we of our and base

to confident our we're that feel by we So back very run normalized QX rate.

David Ryan Lewis

are I fourth follow-up understand it in there. the ex-U.S. signals pretty so And third about Mike. feels in ex-U.S., But And my range I in third, implied. the fourth much. you flattish of and fourth what similar. quarter Shacey maybe be then can would your sort the And recovery of then, guidance guidance fourth? work third for given like how were the the wrong apologize the help expect quarter, drawdown the just bigger Mike, just the and us and if and better quarter wrong? if doing I in if demand the can I'm second Am you do the inventory in through the math a And somewhat said doing math Okay. Thanks

Michael L. Levitz

Sure.

third. clarify, than to so the fourth just So, quarter definitely is the higher

But implies if of high you're a third the higher growth underlying more to $X fourth million range the definitely being see for is I reflective think of quarter being range business. we the and for the range a there flat, in range the the quarter $X fourth. referring the and million end

the through wider give think we wider would say, previously, in inventory to range the time in Generally than it's I would fourth I excess given mentioned the we year, fair we third call. speaking, remaining because the we have at a of have finish that when a the do to quarter third QX quarter. quarter in as this expect work we range

the So I the anything quarter. read on – fourth range into wouldn't wider there's

the this think completed, I just fair a small to thoughtful in we And we want not is the it's very be to given say transition. just quarter guidance.

I with million-plus guidance a were fourth to of we north the think what a And very is business. is trying run do this a million what's is being $XX expectation. guidance the $XXX note that's to rate, quarter strong important international our that what with quarter convey we see business, just in line implies really

Patrick J. Sullivan

And higher profitability.

David Ryan Lewis

Pat. Thanks,

a definitely higher probability. So

back into into was, there give quarter of that expect XXXX do say rate follow-up of as so quick much. think you quarter last example, from you acceleration the the move Thanks when growth, us a you expect general sense in can reflects then And fourth we I'll recovery, the jump for queue. or should XXXX? still you we fourth level could So full just

Shacey Petrovic

I expect about got from is acceleration now the QX What's so we've exciting Europe. in this level. would people XXX

is organization on focused commercial exclusively Omnipod. Our

is we of the to noted, guidance expect and year. Mike then the continue grow continue noise business as broad, and in So through rate at our QX beyond, I just to an transition we think from QX. the as the looking accelerated because But

Operator

Thank you.

Ravi Berenberg line the Misra Capital. from of Our next question comes of

now is open. line Your

Ravi Misra

the Thank hear Can me? taking you Hi, for afternoon. you questions. good

Shacey Petrovic

Yeah.

Ravi Misra

Hi. Great.

margin. on push So question to wanted the just back first the gross

that the us follow-up then, was I underlying of again, of – to business. was my How could much we is tied the basis international that in around kind channel much of points, there should think help direct. that you of that look improvement XXX how business? seems understand going the If mean, on mix churn? kind shift And that adds how and patients of turnover factoring forecasts when be more have control versus you. we of now the at new about kind Thank you patient the of into sort there? it should like some there over we kind But our is

Michael L. Levitz

is the Mike. I'll question take margin gross This and...

Shacey Petrovic

Sure.

Michael L. Levitz

then over Shacey. I'll ... turn it to

In second terms a of the we points XX% my that that with in breakdown X of was had international our the implied improvement and favorable now the approximately do business. is lower a reached quarter, we significant expect much What's the in threshold earlier of base. comments we have mix what where I described now is

looking And to realizing now was at helped mix, end are but so, by our XX% in quarter we in direct not now instead of while Europe, the the we our and we capturing to we favorable are users trend, the going go uplift intermediary. as in the were pricing, forward what

we the the of as and XX% why that that's remainder for expect believe what is base. so, year And our we

Shacey Petrovic

about question and And, the actually, in than lower the is your patients Ravi, is to churn, much Europe U.S. new it in attrition rate

to indication we increased And no approximately that have it's this with So X% has transition. X%. that

we continuity in transition. for approximately as Pat of and of patients, patients we said, XX,XXX fact, confident we've – provided transitioned are very that this that In XXX% that care the

Operator

you. Thank

the line from question next comes William Margaret Kaczor of Blair. of Our

Your line is open. now

Anna Nussbaum

a you and you bit just payors what DASH is little hurdles do from what on feedback patients kind reimbursement is contracts This the push to have or need your guys. and in for transition just and ask Anna wanted Margaret. those Hi, of from DASH to initial data I with Thanks. And do pharmacies? to

Shacey Petrovic

for question. Anna, Thanks, the Sure.

piece phone prime which how a has it a on as minutes designed system so It's is phone So I got and thought that to feedback which the extraordinary the designed X of device, took cell her like one POD, that users, cell and that feedback really learn pretty as it but from intuitive just consumer goes one is was been far we great, of terrific. kind is the the been and of a a platform. system to was

just are easy-to-use the people And so, really with impressed platform.

payors, work to terms change feedback It's not been data in to we establish of business of lot pricing, getting issue. the a In DASH in really channel. the payors great the a it's primarily which as tied is pharmacy model. We're from

So into PDM that and moving pricing the this pricing. is then forward kind eliminating the PODD of moving

occurring that's money been and are payors It's their where crossed the a that product Omnipod enhancing has that's are so very it. hoping of then fingers to just get on advantage people plunking these down And sort payors well responding the and of other been ton keeping further change and that systems already the and a the over stay benefit.

So eliminated we've with. has payors for discussions positively are we and payors that the very in that been hurdle that by currently just received

Operator

Thank you.

question W. next Jeff the from Our comes of line Johnson of Robert Baird.

Your line is now open.

Jeff D. Johnson

Thank you. Good afternoon, guys.

the range around some harder want but on on fourth million, know number. questions. a there's guess about Even let in the we're that's $XX talked you quarter there, growth. all XX% and neighborhood in just XX%, to I But, I little year-over-year international. a quarter of fourth I think have somewhere to that Mike, start I going sure first me So I'm push

price I revenue it core kind would connect ex simple reduction price those the Can uplift, the dots, math there's suggest seems help missing With XX% in like you me been just please? of the something list. all a Am there?

Michael L. Levitz

Sure absolutely.

is $XX million the would the quarter for third between $XX given guided I imply quarter for fourth range million. that year, $XX million. to that to is the and million full what $XX the And So

described. million $XX as So probably above I

year. a would through we're we've built the only there wider you is I again what halfway but range, in on said, as So than basis, a one-quarter

business indicative in you at there believe if is upper we a end more range, isn't which look the really So quarter, direction. our the the for fourth of of underlying change

line. our uplift is revenue given it pricing, If we north our changes and we've is new speaking, And focus on that the said, said and of care initial the also a of in quarter about in big starts, patient you slope any talk that. of really continuity driver this not of XX% generally as are

have excellent the the team an we strong. ground Europe. have running trajectory So is hit and They in

shouldn't from anything And infer than guidance. so, other that this you

Jeff D. Johnson

right. I math doing helpful. That's call. some All And was during the

this, any or timing it, update apologize, launch did I missed and Horizon I pivotal if Shacey So pre-pivotal I'm on you expectations? missed sorry. I but give If kind just of

Shacey Petrovic

No, that's okay.

we We'll pre-pivotal. said share IDE data I a make move IDE into then to we the in September. or decision that wrap then into either with expect that that FDA final whether what and this or a up So take not and was

next call we'll that for the So clarity have on certain.

Jeff D. Johnson

see right the might thoughts if when Expectations, there? any you updated a Horizon had for put U.S. to launch, in now them

Shacey Petrovic

Yeah, into end be XXXX. a lot I the few early path of call one. more not, there that give head able on a still think if months a next timeframe it we clarity for to to and is our pre-pivotal, add we'll If may XXXX, for

the pathway also have Dexcom, which that with meeting a We with that. FDA. tailwind a for the discussing We've and is factor could been the been be iCGM with FDA

be we want the to any next those to all questions just should all give by you further But So guys. that get call. done of guidance of before all answered we

Jeff D. Johnson

Understood. Thank you.

Shacey Petrovic

Yeah.

Operator

you. Thank

comes from Antalffy Partners. Leerink Danielle Our of next question

Your line is now open.

Danielle Antalffy

go device could high Shacey, point around numbers pump level for now Dexcom years on And there the diabetes you've comment Hey, this ADA, or excitement at asking drastic PDM, from (XX:XX:XX) devices change site that ask what I'm Thanks just it How it's I'm of And taking lot like next the are for overall. feel mean guys. was insulin on Thanks pump we're reports is wondering diabetes difference ramp? so could ago. also an question. not market quarter. few you the CGM question. ADA yesterday today? XX at Where It very Where going was a much. the devices, I several a so felt over but year pump could and the if could because you seen a like penetration it penetration? years? you quickly much think strong. Do your overall? U.S. diabetes inflection question for to

Sorry, know I that lot. a was

Shacey Petrovic

agree so there's tremendous least driving Yeah, at things buzz Danielle. two a are problem, of No sort that that. and I been

first I think adoption. the CGM is

people great as a to us for get Omnipod to help more them is want visibility for as great a CGM and because trends, I've adoption control that. their So said, glucose that is tools tool thing typically they always

as also Omnipod see adoption, we see obviously, we more So more CGM adoption.

driving to pathways. are clinical that and driving by to to FDA's is giving these Glucose Control Systems communities interoperability the communities, other to the that's and that thing responsiveness iCGM The industry Automated really the iPump patient and really both like the pathways market

all somewhere think at market X% the that think on grow that really innovation and were years. I five I already X% the could that FDA's we the of front. And CAGR next around pump of we applaud to over bodes well a predicting that So

our that a these I in quarter too. increase think result showing you this trends we had you see as start rate Pat a patients CGM. And record growth actually can of numbers new what; with the it's as that terrific know really fact record referenced well.

in so, business. tailwind and And that certainly momentum we're seeing our

Danielle Antalffy

type in relatively think the if guys Great. I'm we're you follow-up I you just X with I'm opportunity, launch, installed your there. shift strategy? product to But X. have a and go-to-market close come Correct think as around said guys up base of type type XX% I if quick correctly. one past the existing have wrong that remembering Okay. me And we first is X the to

in so and much. to could and So any color how be that beyond? there additive numbers XXXX Thanks

Shacey Petrovic

Sure. Yeah.

certain well available that the that. Danielle, accelerate frankly, ease X of best also which help things type interfaces are like is come Lilly, really business with And features right, the of of received about believe we towards And, course, in type U-XXX then, its you're our products think community. and I because U.S. X. XX% today the with will type X our are have we of that use So patient, user and U-XXX by type improvements geared X pump

in so, the in of segment growth up the of our rest that I segment. come going years to kept as the market. the growth And And those that has to with in believe see population over segment products next the growth few we're in fact, that

which So great. seeing we're continue that grow, to is

Operator

you. Thank

Capital Markets. Our of comes Wuensch next from of question the Joanne line BMO

line is Your open. now

Joanne Karen Wuensch

Two everybody. afternoon, Good questions.

drug comment any anything spent would you or awesome. on any you're And on be that on give like haven't contract Could you'd time us there? if what negotiations We update delivery. seeing an to

Shacey Petrovic

represents really to update. doses. U.S. the an Obviously, excited reporting of you and were give I'll now all that see partnership Neulasta with we strong XX% Amgen Sure. remains injector on-body their the

just there. front. delivery the new strong So report adoption really drug nothing really to There's on

remains We said, have as continue that we discussions and exploratory always work and confidential.

And so much of in stage nature. early what we're discussing is really

much And We really term said this as really those. always see so, another contributor. a need achieve as what we don't to think about that our XXXX we've goals, we longer for Amgen is example,

Joanne Karen Wuensch

follow-up other you. a seems that as me – and in that question, it that we're And us products but new update, where working, that you an the your as Thank little side. to bit give to area on may talking approved, and reimbursement FDA Danielle the any a commentary trifecta have a UnitedHealthcare follow-up Thank you. being be insurers you with? you just And possibly also can

Shacey Petrovic

Sure.

growth took helping terms extraordinary. for Omnipod. It's a great with of to new UnitedHealthcare to So reimbursement access us been patient associated commercial the that the drive really adoption in has and level

or covered that XX% And Omnipod you're we great right. to be. a XX% access virtually now, of So have is I which commercially lives think to place have

In addition really payors patients. making to great innovations innovation, FDA it's available their to see to these the propelling

experience, serve. differentiation, coverage, we coverage for a our so channel terms customer for to broad We Because be and cost started focus has there. that opportunity of in great channel provide to so, lower And a have expanding DASH see the that's to commercial a better us as true. pharmacy competitive in really

all and six So going months. on next then, of And well. the through that's we're for that and is focused Medicaid really very well as where the pull Medicare over course,

Joanne Karen Wuensch

you. Thank

Operator

you. Thank

the question of comes line Our Guggenheim. Pasquale from next of Chris

Your open. line is now

Christopher Pasquale

growth installed expectation we've to wins. encouraging, Thanks. full of base DASH recent The from in the some is and especially access certainly see increase since impact very U.S. market yet your the more

Just talk better than have the expected about of going might the and at year? you what's the start dynamics there

Shacey Petrovic

primarily access installed Sure. driven base wins. Really market that in increase by is the

certainly good have and we new just then then And physicians' offices. starts think well. into That from patient has effect were April went awareness There we're United benefiting in also propelled of So I and X. coverage, there reduction as physicians willing But now product. Medicare or offer barriers some things to without commercial we offer to they were but patient more more product or that willing broadly have the their either to population. thereabouts, who Medicaid, have much early had the more wins Medicare less may those

a U.S. really working favor. been the We have mix in that's working in So quarter little of did business. against us bit our

installed growth But sort right line with of look doesn't growth. access, increase I base revenue that the why think will over an drive all the good in the up revenue so, we which as coming that's is really growth base it's And horizon. and because from out volume market

Christopher Pasquale

And the European then just on one Thanks. business.

or that in piece business The just inventory? third excess $XX underlying and assume additional impact as you trends is inventory guidance, absorb does slower the million channel repurchases done quarter that that really is XQ

Shacey Petrovic

Right.

transition. So the that repurchase What in within our the is into had distributor is sold QX our is growth that inventory the before former implied done. the existing just in was intermediaries excess

normalized and in be through back QX. we'll the to run So that QX in work rate

Christopher Pasquale

Thanks.

Operator

Thank you.

from line Marcus comes Our Robbie next the question JPMorgan. of of

now is open. line Your

Robert J. Marcus

of Europe. you I really the you controls. the built question. where taking Maybe was and quarter didn't when After know in good Chris' there you was put couple up that occurred? Great. inventory question. in how channel realize just happened Thanks on a in that my ago inventory up know did in to channel years for What guys follow much

Shacey Petrovic

Sure, Robbie.

think inventory. this of over of that so extended likely it time. some was is, It's So eight about seven if to probably what period built weeks you

every because growing all why activity that So to the a excess we it quickly. perhaps And not week perspective, did put about was of day so the inventory. for last year was in it's reason a week eliminate of business

growth. had product. customer no wanted that went sure make to and exploding France rapid without it's So we We

not it's We had actually, and ship, so, in place. QX And to great distributor an all QX. our science. orders didn't We former exact really both oversights in

we ultimately growing was, So last of great had how excess. six because oversight we But bit I market of had this think a fast months. little for the the

mitigated is very very, the and think it QX good news ultimately, quickly. reacted is strong. and the team contained QX We it and very business underlying I the to

Michael L. Levitz

what I had we Mike. is earlier, This they'd would on been us remind Shacey before distributor June informed just former the was information is inventories was Yeah. inaccurate. that when our which given mentioned by in

Shacey Petrovic

Yeah.

Michael L. Levitz

So in timing. about the to answer question your

Robert J. Marcus

saying remind the us somewhere size quick for And then, One, you follow-ups. you Okay, do of the two you'll to is? timeframe in ballpark. been of $XX point what just the owe the U-XXX know great. million the Ypsomed And very Thanks. product? payment at can this They've

Michael L. Levitz

take the I'll Robbie, Mike. payment. it's fee

determine the we'll fee. So

as of agreement. as somewhat is a not high And as really a wide definition million. SEC – shipments documents the get the depending the range, in very in as – our reminder, on that upon we've occur to $XX range. the $XX the pretty based upon in defined lead wide agreement. find months. whatnot, next million, information of a the very, the XX kind As necessarily is details reflective that the can specifically it as business It's disclosed And the reflective over fee It's as low into in we defined historically customer customer of and we

that will clearer become And forward. go so, as we

Shacey Petrovic

end market XXXX expect be XXXX. U-XXX, to And the of towards in that we sometime the or

good and making in progress. So development that's currently

Operator

Thank you.

Our J. of the next of Piper McKim P. question from Jaffray. line comes

Your line now open. is

J. P. McKim

weeks Thanks on but pretty that? Hi. here aren't we into the And so, already? good mean back does and three visibility in here three I all have that piece and for like past weeks there's think two I it, question. worked QX inventory QX international wanted the to two the through if you've you where taking in maybe I to go to misunderstood

Shacey Petrovic

has say been strong. I'll July that very Well,

et been validate we're XX% to customer rear-view sensitive to only that cetera, optimistic about feel this with the levels, And for had but also fact we've days. we're intermediaries. do the the our we've we XX% inventory mirror, able to in getting XX that base, So of business

confident that that us terms very us behind indications QX. smaller and by being be the some behind example, of are it the cautious strong for not of But in of intermediaries, could that are area these quite just that of. validated. yet will that we're rest we it we have aware inventory we're haven't I Maybe be think So

J. P. McKim

finally you're That's How how about in you're you want that over side you. Got sounds to you to launch? some just from to on Roche there? I room I And their a just helpful. pump There's ask the your about see but It one. Europe? differentiating have there, and still grow wanted then, you're how competition positioning thinking lot product thinking of for like for

Shacey Petrovic

out We've Sure. about the participating contacted by We Roche's product. the been we're to reached insight trial that certainly some clinical have in with product. UK Roche's into of good customers a in

days a user product, have received what think I don't hearing very that the clinicians they I And from anyone it's So guide. early that we're complex the seen but is it's even know has and product.

Pod one customer In components the the the fixed and process waterproof. before it's guide us and It's sent out a patient. has onto putting not fact, user pointed that XX-step

compelling make that sure the So at that device. and delivering early least it team But like job in certainly I as commercial best days, we user-friendly the fairly think the is to the market. we most best have not customer mechanism seems a complex our and service have

we're on. what certainly that's So focused

J. P. McKim

Thank helpful. you. That's

Shacey Petrovic

Sure.

Operator

Thank you.

Doug of Cowen. Schenkel of Our next question comes one

now line is open. Your

Ryan Blicker

Thanks this on the Last a quarter is talked clearly questions. if This U.S., even United. but distributors happen starting about inventory quarter been on headwind taking for Ryan the my access U.S. Maybe previously great modest much? a and It's Doug. potential from you the Hi. to so, of could how Was for in reduction you quarter have bigger. helping the from in

Shacey Petrovic

I earlier. the United business, the from direct. We just inventory headwind previous serving little a ramped took bit lingering in down that mentioned Yeah, obviously that of Ryan, was have terms that did because we the the distributor of –

We the wins of bit for really is other not against then a little works quarter. Medicare, maybe a in installed surprise impact we but in just that us mix. just had revenue, lingering And that was there have example, shown of is headwind some this a So tied and little bit. to base that

Ryan Blicker

Got it.

next can affect that. update on maybe plant China, X at you all, tensions give tariffs the to then, I if Sorry, footprint? to expect on trade U.S. and over significant us your the manufacturing to XX given new an missed can how, Chinese your And the And operations you supporting moving months a will much sense us capable able you escalate? volume in plant of be XXXX? you. trying new and demand Thank XXXX, to to how tensions XXXX I'm if understand most be your case early just in production ramp in you'll of of to give U.S.

Michael L. Levitz

question. tariff I'll This is take Mike. the

So as we of not tariffs any far. by the are covered described so

standpoint, a does So if supply we on on secondary these But right go. have said, that us we on sources product conversations advance in there us that any focused our that's team directly to and our it's why we'll it's now, chain lost impact from doesn't ready U.S. that very That is something have on have great of have been it in supply broad establishing statements directly. tariffs. about right – now not tariffs been it manufacturing it so of the cover though contingencies doesn't case even

front. So that on comfortable feel we

Shacey Petrovic

In the we up, XXXX. in be so terms ramping will of up ramp

we probably So this a we XXXX, think administration And probably strategically before that U.S. won't business full build XXXX. the in made It'll I manufacturing to serve the be is late news good event. early in decision XXXX U.S. our the the change.

of to, of the So of ahead game end the we XXXX, be we really business the out and by have are the the U.S. able served should of majority vast U.S.

Ryan Blicker

you. Thank great. That's

Operator

from next our Bedford Raymond question And of you. the Thank line James. of comes Jayson

open. now is line Your

Jayson T. Bedford

Good afternoon.

in than were look half the a cost second What lower expecting. like? XXX does OpEx questions. of came reps P&L OpEx we the in Just Europe. assume quick I profitability Mike, is the that couple carrying

Michael L. Levitz

Europe about my year Europe track an direct mentioned the cost on the I $XX international specifically for guidance going So we're basis. business the that your on earlier the of annual for in the to million right run of as into we'd million to and in reps, question comments, rate $XX given

what be. up quarter, expect that we our So line of directly the in our ramping as with been in to we've statements second is previous that, spending to

guidance we've general, In favorable that we terms the OpEx in to of are yeah, given before.

investments other all this force continue we to growth a to years spend if We we need top significant several don't said, significant sales and lot won't. to closely. With very we and the continue we line. That to on are spending And things, something, expect drive of expansion growth. drive making the to innovation next watch

are what yes, So, from our a growth initiatives. standpoint, an we to favorable of short-changing OpEx related to but we guided bit any not to it's growth

Operator

Canaccord our Genuity. Thank Kyle Rose next line comes And of the from question you. of

now open. is line Your

Kyle William Rose

then that's the so in if the been Great. that for we're Thank QX, apologize cited you how update an of payors can And with when Medicaid, from policies you calls, we'll for potential getting think initial are expectations aside you I Medicare answered. as juggling and that the in the with some conversations just give us far a have XXXX? as an coverage impact respect and But for taking on ask to already question. I going formularies back outlook I few your

Shacey Petrovic

Sure. Related Kyle? to you're Medicare, right, I think asking,

Kyle William Rose

Yeah.

Shacey Petrovic

Yeah.

Okay.

the in April that all opened progressing Part CMS negotiations when So, way granted got resonating two designation really yeah, is is those is the guidance proposition indicated I for were that Medicare that's a process well we've or value conversations in January. XXXX. that with have and decisions early clearly payors. CMS think D The In we been of a the works the

successful will end of all August August, really Medicare were. see D top with through we formulary So the through And approximately, how providers. August their having we're in from then and will of we October, they really publish schedules, discussions April Part

XXXX means on established. so, in what broad picture And the coverage well. clear of we've fully we that have next kind have type early full going should the of expect which coverage very November Medicare I is are to So XXXX. think call, or conversations of We

Kyle William Rose

very to Great. the year the I in half of six if an how it days we long-term, and still additional should term there's helpful. expanding expect transition wanted and the all in rather OUS busy it's one realize so you took update about as OUS think And two get maybe you've like early to you business, That's anything to the rights. here. particularly how back on the months then just more as longer a sounds territories Thank into than on about than think next five? rather near-term back far now you. I and medium- three got mean, you that to years But

Shacey Petrovic

a of could for a think were the this I new new market Yeah. which go or strategic constrained question, not it primary our one great making we – and into is because Yeah, market without previously it's just a rationales international distributor. global Kyle, highlights former we decision,

invest So to started our on, that one an of What in seen able of we've who patients be us grow Omnipod never the clinicians' destiny offices our business. and uncovered and main new told international motivators was early control to already we've ability kind of they've that get rep.

going there's be and opportunity So tremendous to from we're of the that's we where grow forward. think right this to through end are where and focused we now year going

available where markets thing is not Omnipod to want European markets. assume see, had bring we've kind though, number think I for an people it's of we logical from international Omnipod contacts of – there today same with increasing and additional to who

currently that to expand right of of XXXX for So that beginning to the to across the in through our Omnipod. would amount XXXX, we that in I would of in come continued a vision has said We some Europe. just building Omnipod strategy our European opportunity see wave into lot new are are. we early And as times, expect growth Pat of the tremendous see continue will is beyond first where grow this markets expect we I a may globe. and many growth grow and we XXXX

the So about support we're really excited that opportunities us.

Kyle William Rose

for taking Thank Great. very you the question. much

Shacey Petrovic

Sure.

Operator

further turn Sullivan. the I back questions this Patrick I'm no over to would you. Thank showing conference like at to time.

Patrick J. Sullivan

to the am very Insulet fruition. company business the the projects I'd I tirelessly of milestones And with the their these $X.X three on Europe job and greatly this in transition the introduction income a will positive for market The achieving the history. two year, these milestones dedication of track over like the a completely thank we time million in operator. also achieved company's work income you, in to Thank bring remain and teams of the achieved years last and performance delighted have for well long-term business. trajectory significant hard for to in of significant first positive add done. key worked the employees our DASH. delighted Congratulations this to all that two quarter: successful the year operating the that that of on we for I'm operating

you the you call very our on today. We third us forward call thank on So quarter Thank joining in conference speaking on to you look much. November.

Operator

Ladies Thank participation for this concludes day. you a conference. gentlemen, and your and today's wonderful have

all You may disconnect.

Insulet (PODD) 2 Aug 182018 Q2 Earnings call transcript